Navigation Links
Microbia Names John McCarthy to Senior Management Team
Date:8/5/2009

Microbia, Inc. (Microbia), an emerging leader in the production of sustainable, specialty ingredients and biomaterials from fermentation technology, has appointed John A. McCarthy Jr. as Senior Vice President Corporate Strategy and Chief Financial Officer. Mr. McCarthy will play a key role for Microbia as the company prepares to introduce its line of natural carotenoid products for the human and animal food ingredient and nutritional supplement markets early next year. For more information about Microbia, please go to www.microbia.com.

Lexington, MA (PRWEB) -- Microbia, Inc. (Microbia), an emerging leader in the production of sustainable, specialty ingredients and biomaterials from fermentation technology, has appointed John A. McCarthy Jr. as Senior Vice President Corporate Strategy and Chief Financial Officer. Mr. McCarthy will have broad responsibility for corporate strategic planning, finance, human resources, corporate communications and information technology as the company prepares to introduce its line of natural carotenoid products for the human and animal food ingredient and nutritional supplement markets early next year.

"Microbia is very pleased to welcome John to the senior management team," stated Richard Bailey, Ph.D., Microbia's President and Chief Executive Officer. "John's extraordinary track record of success in the transformation and growth of science-based companies from research and development-focused organizations to broad commercial entities will be vital as we accelerate our plans to take advantage of the large-scale market opportunities afforded by our technologies."

"I'm very pleased to be joining Microbia at this important time in its development," stated Mr. McCarthy. "The ability to build a unique, low-cost and highly valuable specialty biochemicals franchise based on renewable raw materials presents a tremendous market opportunity for the company, its customers and our environment."

John McCarthy brings 17 years of executive management experience to Microbia from the broad healthcare and alternative energy industries, including having led three IPOs, numerous corporate partnerships, and the raising of over $1 billion of capital in the private and public markets. Most recently, he served as Executive Vice President and Chief Financial Officer of Verenium Corporation, a publicly traded leader in the biofuels industry. At Verenium, Mr. McCarthy was responsible for initiating, developing and executing the plan that created Verenium from the merger of two organizations. He integrated the organizations, raised approximately $200 million of incremental capital for the company and closed a unique strategic partnership with UK-based BP plc worth over $130 million of non-dilutive capital for the company. Prior to Verenium, he served as Senior Vice President and Chief Financial Officer for Xanthus Pharmaceuticals, Senior Vice President Corporate Development and Chief Financial Officer for Synta Pharmaceuticals, Executive Vice President, Chief Operating Officer and Chief Financial Officer for Exact Sciences, and President of the Managed Care Division for Concentra Managed Care.

Mr. McCarthy also worked in the Investment Banking Division of Morgan Stanley and graduated with a Bachelor of Science degree from Lehigh University and an MBA from Harvard Business School.

About Microbia: (www.Microbia.com)
Microbia, Inc. (formerly Microbia Precision Engineering), is an industrial biotechnology company that develops high-value, renewable specialty ingredients and biomaterials by applying its proprietary metabolic engineering to fermentation-based manufacturing. Microbia will develop and market its products through direct sales and strategic alliances, including an on-going multi-product joint development and commercialization agreement with Tate & Lyle. Carotenoids will be the first products launched from Microbia's diverse pipeline of natural specialty ingredients, biopolymers and other biomaterials. Microbia, Inc., based in Lexington, Massachusetts, was established in 2006 as an operationally independent subsidiary of Ironwood Pharmaceuticals, Inc.

# # #

Read the full story at http://www.prweb.com/releases/Microbia/McCarthy/prweb2718134.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Microban Partners With YogaDirect.com to Launch Yoga Mats With Zinc Antimicrobial Technology
2. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
3. Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock
4. Microbia, Inc. Names Alex Chu as Vice President of Process Development
5. MIT reels in RNA surprise with microbial ocean catch
6. Microbia, Inc. Names Mike Doyle as Senior Vice President and General Manager, Nutrition Ingredients
7. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
8. Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees
9. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
10. Microbia PE Adds Nutritional Ingredient Industry Veteran Charles Walton to Senior Management Team
11. Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microbia Names John McCarthy to Senior Management Team
(Date:5/23/2016)... May 23, 2016 - Leading CRO,s Use ... - Frontage Implement a Single Platform to Manage End-to-end Operations ... Within the Bioanalytical lab Frontage Laboratories, a full-service contract ... and China , has selected IDBS, ... In addition to serving as the global electronic lab notebook (ELN), ...
(Date:5/20/2016)... ... 20, 2016 , ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ... treated over 100 of their own patients with the VetStem Cell Therapy. Each of ... care for their patients. , The veterinarians are Dr Ross Rich former owner ...
(Date:5/19/2016)... ... , ... Anton Paar USA, located in Ashland, Virginia is pleased to announce ... structure adds a third office building to the current facilities. , Growth is ... land, along with office space adjacent to the previous main building. Through remodels and ...
(Date:5/19/2016)... Regen BioPharma, Inc ... announced today initiation of a preclinical development program ... cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint. ... generation of cord blood derived killer cells whose ... product in development will be a "universal donor" ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):